Saturday, July 5, 2025 7/5/2025

Integrated Host/Microbe Metagenomics to Improve Lower Respiratory Tract Infection Diagnosis in Critically Ill Children

Award Number: R01HL155418
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2021
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Integrated Host/Microbe Metagenomics to Improve Lower Respiratory Tract Infection Diagnosis in Critically Ill Children - SUMMARY Lower respiratory tract infections (LRTI) lead to more deaths each year in children than any other infectious disease category. Despite this, the underlying microbial pathogens are rarely identified due to the limitations of existing microbiologic tests, resulting in inappropriate antimicrobial use and other adverse outcomes. Viral- bacterial co-infections and non-infectious inflammatory syndromes resembling LRTI, common in critically ill patients, further complicate diagnosis. To address the need for improved respiratory diagnostics, we will leverage an integrated host/microbe metagenomic next-generation sequencing (iHM-mNGS) approach, recently developed by our group, that simultaneously profiles three central elements of LRTI: the pathogen, microbiome and host response, from a single sample of respiratory fluid. We will accomplish our three aims by studying an established prospective, multicenter cohort of 455 critically ill children with acute respiratory failure requiring mechanical ventilation. Aim 1 will develop and test iHM-mNGS classifiers designed to: a) accurately diagnose and differentiate LRTI from non-infectious acute respiratory conditions, and b) rule-out bacterial LRTI with high certainty to permit judicious antimicrobial use. Aim 2 will develop and test a mNGS model for detecting and differentiating LRTI pathogens from airway commensal microbes, and then determine the capacity of the model to identify new, previously missed pathogens, in patients with clinically adjudicated LRTI but negative standard clinical testing. Aim 3 will leverage CRISPR/Cas9 targeted enrichment methods developed by our group to detect pathogen antimicrobial resistance genes, which could more quickly inform appropriate antimicrobial therapy. We will develop and test a model to accurately predict bacterial antimicrobial resistance without a need for culture, and then determine the utility of this approach as a rapid diagnostic using real-time Nanopore sequencing. This study will address the need for better LRTI diagnostics by developing and testing advanced, culture- independent methods that integrate host response and unbiased pathogen detection to achieve accurate LRTI diagnosis and rule-out in a large multicenter cohort. Our methods aim to change the paradigm of pulmonary diagnostics by simultaneously profiling host transcripts and microbial sequences from a single sample of respiratory fluid.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$5,104 )
2025	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Lung Diseases Research	000	4	5/20/2025	NON-COMPETING CONTINUATION	-$5,104
														Subtotal = -$5,104

Issue Date FY: 2024 ( Subtotal = $399,895 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	000	4	11/21/2023	NON-COMPETING CONTINUATION	$399,895
														Subtotal = $399,895

Issue Date FY: 2023 ( Subtotal = $399,895 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	001	3	2/17/2023	NON-COMPETING CONTINUATION	$39,989
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	000	3	12/2/2022	NON-COMPETING CONTINUATION	$359,906
														Subtotal = $399,895

Issue Date FY: 2022 ( Subtotal = $399,895 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	001	2	6/14/2022	NON-COMPETING CONTINUATION	$39,990
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	000	2	11/29/2021	NON-COMPETING CONTINUATION	$359,905
														Subtotal = $399,895

Issue Date FY: 2021 ( Subtotal = $415,270 )
2021	2021	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	001	1	7/3/2021	NEW	$41,527
2021	2021	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Lung Diseases Research	000	1	1/25/2021	NEW	$373,743
														Subtotal = $415,270

Grand Total All Awards = $1,609,851

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrated Host/Microbe Metagenomics to Improve Lower Respiratory Tract Infection Diagnosis in Critically Ill Children

Award Number: R01HL155418

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2021

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer